Literature DB >> 22378261

Maximizing the value of diagnostics in Alzheimer's disease drug development.

Eric M Snyder, Jake Olin, Frank S David.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22378261     DOI： 10.1038/nrd3535

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  5 in total

1.  The Alzheimer's Disease Neuroimaging Initiative: Annual change in biomarkers and clinical outcomes.

Authors:  Laurel A Beckett; Danielle J Harvey; Anthony Gamst; Michael Donohue; John Kornak; Hao Zhang; Julie H Kuo
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

Review 2.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.

Authors:  Harald Hampel; Richard Frank; Karl Broich; Stefan J Teipel; Russell G Katz; John Hardy; Karl Herholz; Arun L W Bokde; Frank Jessen; Yvonne C Hoessler; Wendy R Sanhai; Henrik Zetterberg; Janet Woodcock; Kaj Blennow
Journal:  Nat Rev Drug Discov       Date:  2010-07       Impact factor: 84.694

Review 3.  Trends in risks associated with new drug development: success rates for investigational drugs.

Authors:  J A DiMasi; L Feldman; A Seckler; A Wilson
Journal:  Clin Pharmacol Ther       Date:  2010-02-03       Impact factor: 6.875

4.  Valuation of biomarkers.

Authors:  Orest Hurko; Graham K Jones
Journal:  Nat Rev Drug Discov       Date:  2011-04       Impact factor: 84.694

5.  Dementia assessment in primary care: results from a study in three managed care systems.

Authors:  Linda Boise; Margaret B Neal; Jeffrey Kaye
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2004-06       Impact factor: 6.053
  5 in total
  3 in total

Review 1.  Circulating cell-free microRNA as biomarkers for screening, diagnosis and monitoring of neurodegenerative diseases and other neurologic pathologies.

Authors:  Kira S Sheinerman; Samuil R Umansky
Journal:  Front Cell Neurosci       Date:  2013-09-10       Impact factor: 5.505

2.  Analysis of organ-enriched microRNAs in plasma as an approach to development of Universal Screening Test: feasibility study.

Authors:  Kira S Sheinerman; Vladimir G Tsivinsky; Samuil R Umansky
Journal:  J Transl Med       Date:  2013-12-11       Impact factor: 5.531

3.  Plasma microRNA biomarkers for detection of mild cognitive impairment: biomarker validation study.

Authors:  Kira S Sheinerman; Vladimir G Tsivinsky; Laila Abdullah; Fiona Crawford; Samuil R Umansky
Journal:  Aging (Albany NY)       Date:  2013-12       Impact factor: 5.682
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.